Scleroderma, a rare autoimmune disease, causes skin thickening, organ damage, and requires vigilant preventative care, especially vaccinations, to manage its complex symptoms and reduce complications.

Scleroderma, also known as systemic sclerosis (SSc), is a rare and complex autoimmune disease that affects multiple body systems [1, 3]. It is characterized by three main features: fibrosis (the hardening and scarring of tissues), vasculopathy (abnormalities of blood vessels), and immune system dysfunction [1, 3]. This chronic condition can lead to significant health challenges, high morbidity, and mortality, emphasizing the importance of understanding its symptoms and management strategies [1, 3].

Recognizing the Diverse Symptoms of Scleroderma

Scleroderma can manifest in various ways, affecting different parts of the body. Recognizing these symptoms early is crucial for timely intervention and management.

Skin Involvement: Skin changes are often among the most noticeable symptoms. Patients may experience generalized skin thickening, hyperpigmentation (darkening of the skin), and digital ulcers (sores on the fingers or toes) [2]. The extent of skin involvement can be an important indicator of disease severity [3]. Scleromyxedema, a rarer form of lichen myxedematosus, is characterized by a diffuse papular eruption (small, raised bumps on the skin) with systemic signs and symptoms [4, 7].
Gastrointestinal (GI) Issues: The gastrointestinal tract is frequently affected in scleroderma, with up to 90% of patients experiencing complications [2, 5]. These can range from mild to severe and include:

Severe reflux esophagitis (inflammation of the esophagus due to acid reflux) [2].
Postprandial diffuse abdominal pain, bloating, vomiting, diarrhea, and loss of appetite [2].
Profound unintentional weight loss and cachexia (severe wasting) [2].
Dysphagia (difficulty swallowing), constipation, and peptic ulcers [5, 8].
Less commonly, severe lower GI dysmotility (impaired movement) and intestinal pseudo-obstruction, occurring in approximately 5.4% of patients [2].

Lung and Heart Complications: Scleroderma can severely impact the lungs and heart. Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are among the leading causes of death in patients with SSc [3]. Cardiac involvement significantly affects the overall prognosis, highlighting the need for early risk assessment [8].
Other Systemic Signs: Patients may also present with elevated inflammatory markers such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and positive antinuclear antibodies (ANA) [2].

The Critical Role of Early Diagnosis

Given the multisystem nature and potential severity of scleroderma, early diagnosis is paramount. Research indicates that baseline gastrointestinal symptoms in early SSc can predict progression to significant GI disease and all-cause mortality [5]. Similarly, early identification of cardiac involvement is essential for risk stratification and improving patient outcomes [8]. A prompt and accurate diagnosis allows for the implementation of appropriate management strategies, potentially slowing disease progression and mitigating complications.

Essential Preventative Care and Management

Preventative care and ongoing management are vital for individuals living with scleroderma to reduce the risk of complications and improve quality of life.

Vaccination: Patients with SSc have an increased risk of infections, which can lead to decreased quality of life and increased morbidity and mortality [1]. Despite this, vaccination rates among SSc patients are often lower than in the general population [1]. Furthermore, immunosuppressive medications commonly used in SSc treatment can lead to decreased vaccine seroconversion (the development of protective antibodies) [1]. Therefore, discussing a comprehensive vaccination plan with a healthcare provider is a critical preventative measure.
Targeted Therapies: Pharmacological treatments are guided by national and international guidelines, addressing specific manifestations such as cutaneous involvement, interstitial lung disease, and pulmonary arterial hypertension [3]. For instance, mycophenolate mofetil has been used in the management of severe GI issues [2]. For scleromyxedema, intravenous immunoglobulin (IVIg) remains a central treatment, often alongside other therapies like lenalidomide [4, 7].
Symptomatic and Supportive Care: Beyond specific medications, symptomatic and supportive therapies play a significant role. For GI symptoms, treatments like rifaximin and hyoscin may be used [2]. Emerging therapies are also being developed based on advances in understanding disease mechanisms, including autoimmune dysregulation and fibroblast activation [7].

A Multidisciplinary Approach to Scleroderma Care

Managing scleroderma effectively often requires a multidisciplinary team of healthcare professionals. This team may include rheumatologists, dermatologists, pulmonologists, and cardiopulmonologists, working together to provide comprehensive and individualized care [3]. This collaborative approach ensures that all aspects of the disease, from skin manifestations to lung and heart complications, are monitored and managed appropriately, aiming to improve patient outcomes and quality of life.

Sources

This article summarises published research for a general audience. It is not medical advice — talk to a qualified clinician about your own situation. Need help finding one? Browse doctors.

Scleroderma: Recognizing Symptoms and Essential Preventative Care

Recognizing the Diverse Symptoms of Scleroderma

The Critical Role of Early Diagnosis

Essential Preventative Care and Management

A Multidisciplinary Approach to Scleroderma Care

Sources